Both in Biotechnology
Beam Therapeutics vs Hemab Therapeutics Holdings
Over the past year BEAM returned +7.8% and COAG returned +4.5%; their daily moves had a correlation of 0.31.
BEAM +7.8% COAG +4.5%Growth of $1, one year, split-adjusted
| Metric | BEAM | COAG |
|---|---|---|
| Price | $25.87 | $41.18 |
| Market cap | $2.67B | $1.92B |
| Today | −4.99% | −0.65% |
| 1 month | +5.6% | +32.4% |
| 6 months | −14.0% | — |
| Year to date | −6.7% | — |
| 1 year | +8.7% | — |
| Revenue growth (YoY) | −94.2% | — |
| Gross margin | 100.0% | — |
| Net margin | −25036.3% | — |
| P/E (TTM) | — | — |
| Price / sales | 17.1× | — |
| Net cash | $1.05B | $457.5M |
| Dividend yield | — | — |
| Volatility (60d) | 63.3% | — |
| Short % of float | 32.0% | 20.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).